Zoom Q4 2021 earnings preview
$Zoom Video Communications Inc(ZM.US)$ is an American communications technology company. It provides videotelephony and online chat services through a cloud-based peer-to-peer software platform and is used for teleconferencing, telecommuting, distance education, and social relations.
Zoom may have benefited from a surge in Covid-19 cases in 4Q, with sales still potentially increasing more than 300%.
Though greater competition from Microsoft Teams and Cisco Webex remains a long-term threat, we believe Zoom may acquire a few smaller companies in the collaboration market to stay competitive post-pandemic.
Higher enterprise penetration may stay in focus, but it's unclear if the Zoom Phone service alone will be enough to achieve 100%+ growth for customers, generating over $100,000 in sales.
-Amine Bensaid, Bloomberg Analyst
Further Reading:
NIO Q4 2020 earnings preview
$NIO Inc.(NIO.US)$ is a Chinese automobile manufacturer, specializing in designing and developing electric vehicles. The company is also involved in the FIA Formula E Championship, the first single-seater, all-electric racing series.
Nio's losses may have narrowed during the December quarter, with its record electric-vehicle (EV) deliveries poised to drive revenue growth and scale benefits.
Revenue may have more than doubled vs. a year ago as shipments soared 111%, fueled by a confluence of expanding sales networks and Chinese consumers' growing appetite for luxury EVs.
-Steve Man & Kevin Kim, Bloomberg Analyst
Further Reading:
Novavax Q4 2020 earnings preview
$Novavax Inc(NVAX.US)$ is an American vaccine development company. As of 2020, it had an ongoing Phase III clinical trialin older adults for its candidate vaccine for seasonal influenza, NanoFluand a candidate vaccine (NVX-CoV2373) for prevention of COVID-19.
We expect investors to focus on Novavax, Inc.'s development efforts for its vaccine candidate NVX-CoV2373 when it reports fourth-quarter and full-year 2020 earnings results on Mar 1, after market close.
Shares of Novavax have skyrocketed 119.8% in the year so far compared with the industry's 9.5% increase.
-Nasdaq
Source: Bloomberg
Editor: Zoe, Rachel
Comment(1)
good
Reason For Report